Buprenorphine Induction Beyond the Basics: Micro-induction and how to prevent precipitated withdrawal in the age of synthetic fentanyl analogs

The Poison Control Center’s Opioid Assistance Resource (OAR) is organizing a 4-part virtual webinar series focusing on prescribing, family and pediatric approaches to opioid use disorder (OUD) care, and the landscape of substance and opioid treatment in Philadelphia. 


This series is part of the OAR collection with support from the Health Federation of Philadelphia's Substance Use Response Guidance and Education (SURGE) program


About this event: 
Session #3: October 26, 2022 @ 8:00-9:00am

Registration: https://www.eventbrite.com/e/428726722167

Cost: None

One of the major barriers to buprenorphine maintenance is the fear of precipitated withdrawal during induction. As the drug supply has changed, new approaches to buprenorphine induction are needed. This training will review practices of buprenorphine induction and preventing precipitated withdrawal.     

The Poison Control Center at CHOP provides Philadelphia’s medical community with Opioid Assistance Resource support via our 24/7 phone line: 800-222-1222. OAR is here to help you with managing opioid toxicity and initiating buprenorphine for Opioid Use Disorder.

Presenter: Dr. Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP

Dr. Joseph D'Orazio is an emergency physician, medical toxicologist, and addiction medicine specialist at Lewis Katz School of Medicine at Temple University as well as a medical toxicology consultant for the Poison Control Center at Children’s Hospital of Philadelphia. Dr. D'Orazio is regarded as a regional expert regarding substance use and substance use disorder treatment in Philadelphia.

Moderator: Robert Bassett, DO – Associate Medical Director, Poison Control Center

Introduction: Rachel Linstead Goldsmith, MPA – Comprehensive Opioid Response &Education (CORE) Program Coordinator

This program is designed for Physicians, Nurse Practitioners (NPs), Physician Assistants (PAs), Clinical Nurse Specialists (CNSs), Certified Registered Nurse Anesthetist (CRNAs), and Certified Nurse-Midwifes (CNMs) able to obtain an X waiver from SAMHSA to prescribe buprenorphine and their care team colleagues.

Learning Objectives: Upon completion of this live activity, participants will be able to:                

  1. Describe why standard induction of buprenorphine can lead to precipitated withdrawal. 
  2. Identify practical techniques to prevent precipitated withdrawal.

Supported in part by the Philadelphia Department of Public Health 

Accreditation Statement: The Children's Hospital of Philadelphia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

AMA Credit Designation Statement: The Children's Hospital of Philadelphia designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation in this learning activity meets requirements for 1 hr Opioid-related CME for PA medical Licensure.

Disclosure Statement: Joseph D'Orazio, MD and Robert Bassett, DO (Speakers), Jeanette Trella, PharmD and Lauren Longo, MPH (Course Directors), and Joan Nolan, RN, Rachel Linstead Goldsmith, MPA and Tina Mannices (CME Planners) have no relevant financial relationship with an ineligible company to disclose.

October 26, 2022
8:00 am — 9:00 am
Training Type Special Topics and Series Events